All News
Filter News
Found 54,734 articles
-
RNAi Therapeutics Market Size to Climb USD 4.28 Billion by 2033
4/17/2024
The RNAi therapeutics market size reached a value of USD 1.11 billion by 2023 is expected to surge USD 4.28 billion by 2033, projections indicate an impressive CAGR of 14.9% over the forecast period 2023 – 2033, a study by Towards Healthcare.
-
Life Science Tools Market Size Set to Soar USD 367.16 Billion by 2032
4/17/2024
According to recent study by Towards Healthcare, the life science tools market size was valued at USD 111.28 billion in 2022 and is poised to exceed USD 367.16 billion by 2032, expanding at a CAGR of 13% between 2023 and 2032.
-
Biologics Market Size to Hit Around USD 1. 37 Trillion By 2033
4/17/2024
According to the latest Research by Nova One Advisor, the global biologics market size was exhibited at USD 511.04 billion in 2024 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period 2024 to 2033.
-
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
4/17/2024
Evaxion Biotech A/S announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).
-
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
4/17/2024
Serina Therapeutics, Inc., a clinical-stage biotechnology company focused on developing its proprietary POZ PlatformTM drug delivery technology announced the appointment of Dr. Simba Gill as Executive Chairman.
-
SaponiQx and InvivoGen Announce Agreement for SaponiQx to Supply Cultured Plant Cell QS-21 Adjuvant
4/17/2024
Agenus today announced an agreement to supply InvivoGen with STIMULON cultured plant cell (cpc) QS-21.
-
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
4/17/2024
Novartis announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® treatment for up to six years in recently diagnosed – defined as starting treatment within three years of initial diagnosis – treatment-naïve people living with relapsing multiple sclerosis.
-
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
4/17/2024
Enterome announced database lock of its Phase 2 study of EO2401, in combination with an immune checkpoint inhibitor +/- an anti-VEGF therapy, for the treatment of patients with recurrent glioblastoma.
-
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
4/17/2024
Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis.
-
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
4/17/2024
Genentech, a member of the Roche Group, announced data from the Phase III OCARINA II study of Ocrevus®, an investigational twice-yearly, 10-minute subcutaneous injection.
-
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
4/17/2024
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that...
-
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
4/17/2024
Enanta Pharmaceuticals, Inc. today announced that data from the company’s SPRINT study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.
-
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
4/17/2024
Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.
-
A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged patent infringement related to their COVID-19 vaccine Comirnaty.
-
Viral Vector and Plasmid DNA Manufacturing Market Size, CAGR, Share, Report 2024 to 2033
4/16/2024
According to Vision Research Reports, the global viral vector and plasmid DNA manufacturing market size was estimated at around USD 5.37 billion
-
Plasmid DNA Manufacturing Market Size to Increase USD 12.36 billion by 2033
4/16/2024
According to Vision Research Reports, the global plasmid DNA manufacturing market size was estimated at USD 1.83 billion in 2023
-
Agricultural Biotechnology Market is Projected to Achieve Sustainable Growth 8.6%
4/16/2024
According to Precedence Research, the global agricultural biotechnology market was evaluated at USD 115.26 billion in 2023
-
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
4/16/2024
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Hart-Scott-Rodino waiting period has expired with respect to its global license with AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.
-
VBI Vaccines Reports Full Year 2023 Financial Results
4/16/2024
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
-
Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development
4/16/2024
Chimeron Bio, a Philadelphia -headquartered biotech company, has received a 2024 National Institutes of Health's Small Business Innovation Research Innovative Concept Award through the National Cancer Institute.